Jeffrey Landau

Corporate Officer/Principal bij CYTOMX THERAPEUTICS, INC.

Vermogen: 200 158 $ op 31-05-2024

46 jaar

Health Technology

Consumer Services

Actieve functies van Jeffrey Landau

Bedrijven	Functie	Begin	Einde
CYTOMX THERAPEUTICS, INC.	Corporate Officer/Principal	01-04-2021	-

Bedrijven	Functie	Begin	Einde
CATALYST BIOSCIENCES	Corporate Officer/Principal	18-04-2016	01-03-2021
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Verkoop & Marketing	01-01-2012	-

Virginia Polytechnic Institute & State University	Undergraduate Degree
Stanford Graduate School of Business	Masters Business Admin

Internationaal

Verenigde Staten

Operationeel

Corporate Officer/Principal	2
Undergraduate Degree	1
Masters Business Admin	1

Sectoraal

Health Technology	4
Consumer Services	3

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
CYTOMX THERAPEUTICS, INC.	Health Technology

Bedrijven in privébezit	2
Catalyst Biosciences, Inc. Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.	Health Technology
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology

Bedrijven in privébezit

Health Technology